Table 4.

Multivariate logistic analysis grouped by type of therapy

	Rapid viral response		Lead-in	Undetectable or VL ≤15 UI
Type of therapy	OR	95% CI	p Value	OR	95% CI	p Value
Treatment initiation (Season A vs Season B	43.31	1.88 to 996.65	0.019	3.36	1.10 to 10.16	0.031
HCV RNA (≤600 000 vs >600 000 IU/mL)	23.95	2.75 to 208.41	0.004	8.86	3.02 to 25.94	<0.001
IL-28 polymorphism (CC vs no CC)	7.29	0.94 to 56.17	0.056	4.00	1.34 to 11.94	0.013
Naïve vs experienced	5.68	0.591 to 54.56	0.132	1.02	0.37 to 2.86	0.959
Genotype (1b vs 1a)	0.18	0.02 to 1.62	0.128	0.55	0.17 to 1.799	0.328
Diabetes mellitus (no vs yes)	0.27	0.02 to 3.62	0.326	0.98	0.19 to 0.87	0.985
Age (≥50 vs <50 years)	2.78	0.44 to 17.65	0.276	1.38	0.48 to 3.97	0.542
Fibrosis (≥F3 vs <F3)	3.69	0.22 to 62.58	0.365	0.98	0.17 to 5.63	0.987
	Rapid viral response		Without lead-in	Undetectable or VL ≤15 UI
Type of therapy	OR	95% CI	p Value	OR	95% CI	p Value
Treatment initiation (Season A vs Season B	1.78	1.93 to 2.90	0.021	1.61	0.86 to 3.01	0.131
HCV RNA (≤600 000 vs >600 000 IU/mL)	1.76	1.04 to 3.00	0.035	3.11	1.32 to 7.30	0.009
IL-28 polymorphism (CC vs no CC)	1.81	1.03 to 3.16	0.037	1.84	0.83 to 4.08	0.132
Naïve vs experienced	1.51	0.87 to 2.63	0.138	0.66	0.32 to 1.36	0.267
Genotype (1b vs 1a)	1.52	0.81 to 2.84	0.191	0.74	0.33 to 1.64	0.468
Diabetes mellitus (no vs yes)	1.36	0.64 to 2.85	0.416	1.57	0.67 to 3.67	0.296
Age (≥50 vs <50 years)	0.83	0.49 to 1.40	0.488	0.87	0.44 to 1.69	0.684
Fibrosis (≥F3 vs <F3)	0.88	0.48 to 1.60	0.681	1.89	0.82 to 4.38	0.133